Opportunity for Investors to Lead a Securities Fraud Lawsuit Against Aquestive Therapeutics, Inc.

Legal Update: Investors Take Action Against Aquestive Therapeutics, Inc.

In the world of investing, staying informed is crucial, and recent developments around Aquestive Therapeutics, Inc. (NASDAQ: AQST) have caught the attention of many investors. The Rosen Law Firm, known for advocating investor rights, has issued an important reminder for those who purchased shares of Aquestive between June 16, 2025, and January 8, 2026. As we approach the lead plaintiff deadline on May 4, 2026, affected investors need to be aware of their rights and options.

The Class Action Opportunity

If you bought securities of Aquestive during the specified period, you might be eligible for compensation through a class action lawsuit without any upfront costs thanks to a contingency fee arrangement. Joining the class action involves no payment out of pocket, ensuring anyone can pursue justice without financial strain.

To participate, investors can either visit the Rosen Law Firm’s website or directly contact Phillip Kim, Esq. The firm encourages potential lead plaintiffs to act promptly, as they must file with the court by the upcoming May deadline. Serving as a lead plaintiff means representing fellow investors in guiding the litigation process, a significant responsibility that comes with the opportunity to influence the outcome of the case.

Why Choose Rosen Law Firm?

Rosen Law Firm emphasizes the importance of selecting experienced legal representation when pursuing a securities class action. Many firms may lack the necessary expertise and resources, merely acting as intermediaries. In contrast, Rosen Law Firm has a solid track record in handling securities fraud cases. They have recovered hundreds of millions for investors, boasting a history of successful settlements and recognitions, including being ranked first for securities class action settlements in 2017. The firm’s founding partner, Laurence Rosen, is a well-regarded figure in the field, recognized for his accomplishments.

Core Details of the Case

The lawsuit centers on allegations that Aquestive made false or misleading statements concerning its New Drug Application (NDA) for Anaphylm. Importantly, the lawsuit indicates that the company downplayed significant human factors involved in using its sublingual film product, including issues related to packaging, administration, and labeling practices. As these details became public knowledge, they reportedly hurt investors, leading to significant claims for damages.

In summary, if you purchased stock in Aquestive Therapeutics during the specified timeframe, now is the time to act. Whether you decide to join as a class member or aspire to become the lead plaintiff, ensure you do so before the May 4, 2026 deadline. Remember, as stated by Rosen Law Firm, investors are not legally represented unless they choose a counsel, so it’s beneficial to seek advice at this stage. If you're unsure what actions to take, consider reaching out for further information and guidance. Keeping abreast of your rights in financial dealings is an essential part of being a savvy investor.

For further updates and guidance, follow the Rosen Law Firm’s profiles on various social media platforms including LinkedIn, Twitter, and Facebook, ensuring you remain informed about your investments.

Contact Information:
Phillip Kim, Esq.
Rosen Law Firm, P.A.
New York, NY
Tel: 866-767-3653
Email: [email protected]
Website: www.rosenlegal.com